NCT06109155 The Effect of ACT and Tranexamic Acid on Bleeding in Cardiac Surgery
| NCT ID | NCT06109155 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Taichung Veterans General Hospital |
| Condition | Surgery, Cardiac |
| Study Type | INTERVENTIONAL |
| Enrollment | 150 participants |
| Start Date | 2024-02-08 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 150 participants in total. It began in 2024-02-08 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to the dose effect of tranexamic acid and the level of ACT on bleeding in adult cardiac surgery. The main questions it aims to answer are: 1. Does higher dose of tranexamic acid reduce the amount of bleeding and blood transfusion? 2. Does lower ACT level during cardiac surgery reduce the amount of bleeding and blood transfusion? Participants will divided into four groups which have different tranexamic acid dose and ACT level during cardiac surgery to see if there is any different in the amount of bleeding and blood transfusion.
Eligibility Criteria
Inclusion Criteria: * adult, cardiac surgery with cardiopulmonary bypass Exclusion Criteria: * pregnant * emergency procedure * immune compromised * aortic surgery * end-stage renal disease * liver disease * critical status * incomplete clinical data
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06109155 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Surgery, Cardiac. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06109155 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT06109155 currently recruiting?
Yes, NCT06109155 is actively recruiting participants. Contact the research team at adconvert98@gmail.com for enrollment information.
Where is the NCT06109155 trial being conducted?
This trial is being conducted at Taichung, Taiwan, Taichung, Taiwan.
Who is sponsoring the NCT06109155 clinical trial?
NCT06109155 is sponsored by Taichung Veterans General Hospital. The trial plans to enroll 150 participants.